Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Comprehensive overview of management and risk assessment of breast cancer-related lymphedema: a multidisciplinary approach

Knopf E., Childers LT., Woodward M., Gray IM., Childers JT., Ahmad S.

Narrative Review, published in Front Oncol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Oncol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42239896
PMCID
PMC13225956
DOI
10.3389/fonc.2026.1796657

Abstract (original English)

Breast cancer is one of the most commonly diagnosed cancers worldwide, with a particularly high incidence in women. Although many are cured of their malignancy, treatment options can present with significant long-term complications for the patient. Lymphedema is the accumulation of protein-rich fluid that occurs following a disturbance to the lymphatic system. Secondary lymphedema to the arm often results following breast surgery or axillary lymph node dissection, although risk and exacerbating factors include radiation and medical chemotherapy, both in the short- and long-term intervals. Breast cancer-related lymphedema (BCRL) develops secondary to treatment-related lymphatic injury, commonly involving the axillary lymphatic system, with clinical manifestations that may affect the ipsilateral arm, hand, breast, chest wall, and axilla. This article serves as an updated and comprehensive review of the available peer-reviewed literature regarding the pathophysiology, incidence, predictive/risk factors, clinical features, diagnostic strategies, comparative accuracy and utility of early detection and surveillance approaches, preventive strategies, and guidelines-based conservative/surgical/emerging management approaches for BCRL. The purpose of this review is to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regarding BCRL.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.